Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.

Saved in:

Bibliographic Details
Title:	Vi polysaccharide and conjugated vaccines afford similar early, IgM or IgG-independent control of infection but boosting with conjugated Vi vaccines sustains the efficacy of immune responses.
Authors:	Jossi SE; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Arcuri M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.; GSK Vaccines Institute for Global Health SRL, Siena, Italy., Alshayea A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Persaud RR; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Marcial-Juárez E; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Palmieri E; GSK Vaccines Institute for Global Health SRL, Siena, Italy., Di Benedetto R; GSK Vaccines Institute for Global Health SRL, Siena, Italy., Pérez-Toledo M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Pillaye J; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Channell WM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Schager AE; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Lamerton RE; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Cook CN; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Goodall M; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Haneda T; Laboratory of Microbiology, School of Pharmacy, Kitasato University, Tokyo, Japan., Bäumler AJ; Department of Medical Microbiology and Immunology, School of Medicine, University of California, Davis, CA, United States., Jackson-Jones LH; Division of Biomedical and Life Sciences, Lancaster University, Lancaster, United Kingdom., Toellner KM; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., MacLennan CA; Bill & Melinda Gates Foundation, London, United Kingdom.; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom., Henderson IR; Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD, Australia., Micoli F; GSK Vaccines Institute for Global Health SRL, Siena, Italy., Cunningham AF; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Source:	Frontiers in immunology [Front Immunol] 2023 Mar 23; Vol. 14, pp. 1139329. Date of Electronic Publication: 2023 Mar 23 (Print Publication: 2023).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1664-3224
DOI:	10.3389/fimmu.2023.1139329